MIAMI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...
SAB BIO, a clinical-stage biopharmaceutical company focused on developing immunotherapy for type 1 diabetes (T1D), announced its financial results for Q1 2025, highlighting substantial progress in its ...
MIAMI, Dec. 17, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results